The effectiveness and potential application of this compound in patients are demonstrated by the reduction in these proteins and the suppression of growth in tumor organoids derived from CRC patient tissues harboring both APC and KRAS mutations. This evidence concerns the gene KRAS and colorectal carcinoma.